Newswire (Published: Monday, July 31, 2017, Received: Thursday, July 27, 2017, 6:58:12 PM CDT)

Word Count: 513

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from Milan, Italy, by NewsRx correspondents, research stated, "The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. In this collaborative review article, we examine recent literature regarding low-risk PCa and the available prognostic and therapeutic options."

Our news editors obtained a quote from the research from the Division of Oncology, "Evidence acquisition: We performed a literature review of the Medline, Embase, and Web of Science databases. The search strategy included the terms: prostate cancer, low risk, active surveillance, focal therapy, radical prostatectomy, watchful waiting, biomarker, magnetic resonance imaging, alone or in combination. Evidence synthesis: Prospective randomized trials have failed to show an impact of radical treatments on cancer-specific survival in low-risk PCa patients. Several series have reported the risk of adverse pathologic outcomes at radical prostatectomy. However, it is not clear if these patients are at higher risk of death from PCa. Longterm follow-up indicates the feasibility of active surveillance in low-risk PCa patients, although approximately 30% of men starting active surveillance undergo treatment within 5 yr. Considering focal therapies, robust data investigating its impact on long-term survival outcomes are still required and therefore should be considered experimental. Magnetic resonance imaging and tissue biomarkers may help to predict clinically significant PCa in men initially diagnosed with low-risk disease. The incidence of low-risk PCa has increased in recent years. Only a small proportion of men with low-risk PCa progress to clinical symptoms, metastases, or death and prospective trials have not shown a benefit for immediate radical treatments. Tissue biomarkers, magnetic resonance imaging, and ongoing surveillance may help to identify those men with low-risk PCa who harbor more clinically significant disease. Patient summary: Low-risk prostate cancer is very common. Active surveillance has excellent long-term results, while randomized trials have failed to show a beneficial impact of immediate radical treatments on survival."

According to the news editors, the research concluded: "Biomarkers and magnetic resonance imaging may help to identify which men may benefit from early treatment."

For more information on this research see: Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017;72(2):238-249. European Urology can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier -; European Urology -

The news editors report that additional information may be obtained by contacting M. Moschini, IRCCS Osped San Raffaele, URI, Div Oncol, Unit Urol, Milan, Italy. Additional authors for this research include P.R. Carroll, S.E. Eggener, J.I. Epstein, M. Graefen, R. Montironi and C. Parker (see also Oncology - Prostate Cancer).

Keywords for this news article include: Milan, Italy, Europe, Magnetic Resonance, Article Review, Diagnostics and Screening, Risk and Prevention, Epidemiology, Clinical Trials and Studies, Prostatic Neoplasms, Clinical Research, Prostate Cancer, Oncology, Division of Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Southern Europe
Western Europe


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
      Treatments and Therapies
            Medicinal Drugs